Biogen Gains Approval for MS Drug

The U.S. Food and Drug Administration (FDA) has approved the use of tecfidera, Biogen's (NASDAQ: BIIB  ) new oral treatment for people afflicted with recurring symptoms of MS, the company announced.

Tecfidera had undergone extensive testing prior to receiving FDA approval, including studying the results of more than 2,600 patients using tecfidera, some longer than four years. The studies indicate tecfidera is successful in reducing brain lesions and minimizing relapses, and even slowing the progression of MS.

CEO of Biogen, George Scangos PhD, said, "We will offer the MS community a treatment with strong efficacy and a favorable safety profile in the convenience of a pill -- a combination we believe will have a significant positive impact on the way people live with this chronic disease." Tecfidera is Biogen's fourth medication targeting MS, and is currently under regulatory review in Switzerland, Canada, and Australia.

With the FDA approval behind it, Biogen will begin making tecfidera available to U.S. patients "in the coming days," according to the announcement. 

 

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2337748, ~/Articles/ArticleHandler.aspx, 9/20/2014 10:25:54 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement